Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 505 Results

Page 14 of 51« First «...12 131415 16...20 30 40...»Last »

November 9, 2022

DBV Technologies to Highlight New Clinical Data at ACAAI 2022

November 3, 2022

DBV Technologies Reports Third Quarter Financial Results and Business Update

October 31, 2022

DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update

October 3, 2022

DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors

September 21, 2022

DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial

September 7, 2022

DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut-Allergic Children Ages 4 to 7 Years

September 2, 2022

DBV Technologies to Present at Upcoming Investor Conferences

August 1, 2022

DBV Technologies Reports Second Quarter 2022 Financial Results

July 27, 2022

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

June 29, 2022

DBV Technologies to Participate in Upcoming EAACI 2022 Congress

Page 14 of 51« First «...12 131415 16...20 30 40...»Last »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Cookies Policy

Scroll to Top